Literature DB >> 2549241

Increment of Tal positive cells in peripheral blood from patients with rheumatoid arthritis.

H Nakao1, K Eguchi, A Kawakami, K Migita, T Otsubo, Y Ueki, C Shimomura, H Tezuka, M Matsunaga, K Maeda.   

Abstract

Recently it was demonstrated that the Tal antigen is a marker for activated T cells and the population of Tal+ cells includes memory T cells. Our study was undertaken to analyze Tal+ cells in peripheral blood from patients with rheumatoid arthritis (RA) and examine the correlation between the proportion of Tal+ cells and disease activity. Using a dual immunofluorescent method, T cell subsets were analyzed in peripheral blood from 46 patients with RA, 10 patients with osteoarthritis (OA) and 10 healthy subjects. Patients with RA had a significantly higher percentage of T cells bearing the Tal antigen than patients with OA and healthy subjects. Furthermore, the percentage of CD3+Tal+ cells in peripheral blood from patients with RA was significantly correlated with disease activity including erythrocyte sedimentation rate, morning stiffness and the Lansbury index, whereas CD3+ HLA-DR+ cells did not correlate. In serial observations in patients with RA, the percentage of CD3+ Tal+ cells decreased in accordance with the improvement of disease activity. Thus, we suggest that the percentage of Tal+ cells may be a marker of the disease activity in patients with RA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549241

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients.

Authors:  Miguel Cuchacovich; Héctor Gatica; Paula Vial; Jorge Yovanovich; Salvatore V Pizzo; Mario Gonzalez-Gronow
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation.

Authors:  H Ikushima; Y Munakata; T Ishii; S Iwata; M Terashima; H Tanaka; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

3.  Different regulatory effects of pentoxifylline on human T cell activation pathways.

Authors:  R P Dong; Y Umezawa; H Ikushima; Y Munakata; S F Schlossman; C Morimoto
Journal:  J Clin Immunol       Date:  1997-05       Impact factor: 8.317

Review 4.  Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

Authors:  Barbara Sperner-Unterweger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease.

Authors:  Aristo Vojdani; Mohsen Bazargan; Elroy Vojdani; John Samadi; Alen A Nourian; Navid Eghbalieh; Edwin L Cooper
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

6.  Blood lymphocyte subsets in rats with adjuvant arthritis.

Authors:  A Franch; C Castellote; M Castell
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

7.  Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon gamma and tumor necrosis factor alpha with the characteristics of peripheral blood mononuclear cells.

Authors:  S Sakito; Y Ueki; K Eguchi; Y Kawabe; S Nagataki
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity.

Authors:  Lucie Sromova; Petr Busek; Liliana Sedova; Aleksi Sedo
Journal:  BMC Musculoskelet Disord       Date:  2015-09-09       Impact factor: 2.362

Review 9.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.